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Summary
 
The class II major histocompatibility complex molecule I-A
 
g7
 
 is strongly linked to the develop-
ment of spontaneous insulin-dependent diabetes mellitus (IDDM) in non obese diabetic mice
and to the induction of experimental allergic encephalomyelitis in Biozzi AB/H mice. Structurally,
it resembles the HLA-DQ molecules associated with human IDDM, in having a non-Asp resi-
due at position 57 in its 
 
b
 
 chain. To identify the requirements for peptide binding to I-A
 
g7
 
 and
thereby potentially pathogenic T cell epitopes, we analyzed a known I-A
 
g7
 
-restricted T cell
epitope, hen egg white lysozyme (HEL) amino acids 9–27. NH
 
2
 
- and COOH-terminal trun-
cations demonstrated that the minimal epitope for activation of the T cell hybridoma 2D12.1
was M12-R21 and the minimum sequence for direct binding to purified I-A
 
g7
 
 M12-Y20/
K13-R21. Alanine (A) scanning revealed two primary anchors for binding at relative positions
(p) 6 (L) and 9 (Y) in the HEL epitope. The critical role of both anchors was demonstrated by
incorporating L and Y in poly(A) backbones at the same relative positions as in the HEL
epitope. Well-tolerated, weakly tolerated, and nontolerated residues were identified by analyz-
ing the binding of peptides containing multiple substitutions at individual positions. Optimally,
p6 was a large, hydrophobic residue (L, I, V, M), whereas p9 was aromatic and hydrophobic (Y
or F) or positively charged (K, R). Specific residues were not tolerated at these and some other
positions. A motif for binding to I-A
 
g7
 
 deduced from analysis of the model HEL epitope was
present in 27/30 (90%) of peptides reported to be I-A
 
g7
 
–restricted T cell epitopes or eluted
from I-A
 
g7
 
. Scanning a set of overlapping peptides encompassing human proinsulin revealed
the motif in 6/6 good binders (sensitivity 
 
5
 
 100%) and 4/13 weak or non-binders (specificity 
 
5
 
70%). This motif should facilitate identification of autoantigenic epitopes relevant to the patho-
genesis and immunotherapy of IDDM.
 
N
 
on obese diabetic (NOD)
 
1
 
 mice develop autoim-
mune, T cell–mediated destruction of pancreatic islet
 
b
 
 cells and are a model of human insulin-dependent diabe-
tes mellitus (IDDM) (1). In common with humans who
develop IDDM, NOD mice have immune responses to is-
let autoantigens such as insulin and glutamic acid decarbox-
ylase (GAD). In addition, they share a structurally similar
class II MHC molecule associated with disease susceptibil-
ity. This molecule, I-A
 
g7
 
, has a 
 
b
 
 chain sequence otherwise
found only in Biozzi AB/H mice that are susceptible to
chronic relapsing experimental allergic encephalomyelitis
(CR-EAE) (2). It is characterized by a non-Asp residue at
position 57 (3), as in the 
 
b
 
 chain of the HLA-DQ mole-
cules associated with human IDDM (4). The capacity of
these unique class II molecules to bind and present peptides
to autoreactive T cells could be critical in the development
of IDDM and CR-EAE.
Although amino acid motifs for peptides that bind to in-
dividual class I and some class II MHC molecules have been
well defined (5, 6), the rules that govern binding of pep-
tides to I-A
 
g7
 
 are still unclear. Reich et al. (7) eluted and se-
quenced several naturally processed peptides from I-A
 
g7
 
and concluded that binding may require an acidic residue
in the COOH terminus of the peptide. Carrasco-Marin et
al. (8) found that I-A
 
g7
 
 either on the surface of antigen-pre-
senting cells or in SDS-PAGE after its purification was un-
stable and that the binding of known I-A
 
g7
 
–restricted T cell
 
1
 
Abbreviations used in this paper:
 
 CR-EAE, chronic relapsing experimental
allergic encephalomyelitis; DOC, sodium deoxycholate; EAE, experi-
mental allergic encephalomyelitis; GAD, glutamic acid decarboxylase;
HEL, hen egg white lysozyme; IDDM, insulin-dependent diabetes mellitus;
MOG, myelin oligodendrocyte glycoprotein; MSA, mouse serum albumin;
NOD, nonobese diabetic; OGP, octyl-
 
b
 
-
 
D
 
-glucopyranoside; p, position;
PEG, polyethylene glycol;
 
 
 
PLP, proteolypid protein; RT, room temperature. 
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epitopes or the peptides eluted by Reich et al. (7) was diffi-
cult or impossible to demonstrate. This led them to hypoth-
esize that weak peptide binding by I-A
 
g7
 
 militated against
elimination of autoreactive T cells in the NOD mouse.
Amor et al. (9) investigated the fine specificity of peptides
from myelin oligodendrocyte glycoprotein (MOG) or pro-
teolipid protein (PLP) for the induction of experimental al-
lergic encephalomyelitis (EAE) in Biozzi AB/H mice and
suggested a core motif for I-A
 
g7
 
 binding peptides.
In this study, we used the I-A
 
g7
 
–restricted T cell epitope,
hen egg white lysozyme (HEL) amino acids 9–27, as a tem-
plate with which to analyze the amino acid sequence of
peptides that bind to purified, native I-A
 
g7
 
 and activate a T
cell hybridoma. This has enabled us to define general rules
that identify most known I-A
 
g7
 
 binding peptides.
 
Materials and Methods
 
Purification of I-A
 
g7
 
.
 
I-A
 
g7
 
 protein was affinity-purified from
detergent lysates of 4G4.7 B cell hybridoma cells by desorption
from OX-6 mouse monoclonal antibody. The 4G4.7 B cell hybrid-
oma was derived by polyethylene glycol (PEG)-induced fusion of
NOD mouse T cell–depleted splenocytes with the HAT-sensitive
A20.2J lymphoma line (10). OX-6 is a mouse monoclonal IgG1
antibody against an invariant determinant of rat Ia, which also recog-
nizes I-A
 
g7
 
 but not I-A
 
d
 
 (11, 12). Approximately 15 mg of OX-6 an-
tibody was first bound to 4 ml of protein A–Sepharose 4 Fastflow
(Pharmacia, Uppsala, Sweden) and then chemically cross-linked to
the protein A with dimethyl pimelimidate dihydrochloride (Sigma
Chemical Co., St. Louis, MO) in sodium borate buffer, pH 9.0. Af-
ter 60 min at room temperature (RT), the reaction was quenched
by incubating the Sepharose in 0.2 M ethanolamine, pH 8.0, for
60 min at RT. The suspension was washed thoroughly in PBS
and stored in PBS, 0.02% sodium azide (NaN
 
3
 
).
4G4.7 cells were harvested by centrifugation, washed in PBS,
resuspended at 10
 
8
 
 cells/ml of lysis buffer, and then allowed to
stand at 4
 
8
 
C for 120 min. The lysis buffer was 0.05 M sodium
phosphate, pH 7.5, containing 0.15 M NaCl, 1% (vol/vol) NP-
40 detergent and the following protease inhibitors: 1 mM phen-
ylmethylsulphonyl fluoride, 5 mM 
 
e
 
-amino-
 
n
 
-caproic acid and
10 
 
m
 
g/ml each of soybean trypsin inhibitor, antipain, pepstatin,
leupeptin and chymotrypsin. Lysates were cleared of nuclei and
debris by centrifugation at 27,000 
 
g
 
 for 30 min and stored as such
if not immediately processed further. To the postnuclear superna-
tant was added 0.2 vol of 5% sodium deoxycholate (DOC). After
mixing at 4
 
8
 
C for 10 min, the supernatant was centrifuged at
100,000 
 
g
 
 at 4
 
8
 
C for 120 min, carefully decanted, and filtered
through a 0.45-
 
m
 
m nylon membrane. The lysate of 5 
 
3
 
 10
 
10
 
4G4.7 cells was gently mixed overnight at 4
 
8
 
C with 4 ml of OX-
6–protein A–Sepharose, and the suspension then poured into a
column and washed with at least 50 vol each of buffers A, B, and
C. Buffer A was 0.05 M Tris, pH 8.0, 0.15 M NaCl, 0.5% NP-
40, 0.5% DOC, 10% glycerol, and 0.03% NaN
 
3
 
; buffer B was
0.05 M Tris, pH 9.0, 0.5 M NaCl, 0.5% NP-40, 0.5% DOC,
10% glycerol, and 0.03% NaN
 
3
 
; buffer C was 2 mM Tris, pH 8.0,
1% octyl-
 
b
 
-
 
d
 
-glucopyranoside (OGP), 10% glycerol, and 0.03%
NaN
 
3
 
. Bound I-A
 
g7
 
 was eluted with 50 mM diethylamine HCl,
pH 11.5 in 0.15 M NaCl, 1 mM EDTA, 1% OGP, 10% glycerol,
and 0.03% NaN
 
3
 
, and immediately neutralized with 1 M Tris.
 
Peptide Synthesis.
 
Peptides were synthesized with a multiple
peptide synthesizer (model 396; Advanced ChemTech, Louis-
ville, KY) using Fmoc chemistry and solid phase synthesis on
Rink Amide resin. All acylation reactions were effected with a
threefold excess of activated Fmoc amino acids, and a standard
coupling time of 20 min was used. Each Fmoc amino acid was
coupled at least twice. Cleavage and side chain deprotection was
achieved by treating the resin with 90% trifluoroacetic acid, 5%
thioanisole, 2.5% phenol, 2.5% water. The indicator peptide for
the binding assay was biotinylated before being cleaved from resin
by coupling two 6-aminocaproic acid spacers on the NH
 
2
 
 termi-
nus and one biotin molecule sequentially, using the above-described
procedure. Individual peptides were analyzed by reverse-phase
HPLC and those used in this study were routinely 
 
>
 
85% pure.
 
T Cell Hybridoma.
 
Hybridoma 2D12.1 was generated by PEG-
induced fusion of HEL-immune lymph node cells from a NOD
mouse with the TCR-
 
a
 
/
 
b
 
–negative variant of the BW5147 thy-
moma, as described previously (13). Reactivity of 2D12.1 to HEL
peptides was assayed by incubating 2.5 
 
3
 
 10
 
5
 
 NOD spleen cells
and HEL peptides (0.3 nM to 10 
 
m
 
m) with 5 
 
3
 
 10
 
4
 
 T hybridoma
cells/well. Culture medium was RPMI 1640 supplemented with
10% FCS, 2 mM 
 
l
 
-glutamine, 50 
 
m
 
g/ml gentamicin, and 50
 
m
 
m 2-mercaptoethanol. After 24 h of culture, 50 
 
m
 
l of superna-
tants were transferred to culture wells containing 10
 
4
 
 IL-2–
responsive CTLL-2 cells. During the final 4 h of a 24-h culture,
CTLL-2 cells were pulsed with 1 
 
m
 
Ci [
 
3
 
H]thymidine. Thymidine
incorporation was measured by scintillation spectrometry. The
concentration of peptide that caused 50% of maximum stimula-
tion is referred to as SC
 
50
 
.
 
I-A
 
g7
 
 Peptide-binding Assay.
 
Peptides were dissolved at 10 mM
in DMSO and diluted into 20% DMSO/PBS for assay. Indicator
I-A
 
g7
 
 binding peptide, HEL 10–23, was synthesized with a biotin
molecule and two spacer residues at the NH
 
2
 
 terminus. Approxi-
mately 200 nM of this biotinylated HEL peptide and each test
peptide in seven concentrations ranging from 50 
 
m
 
M to 50 pM,
Figure 1. Examples of competition between biotinylated HEL peptide
(amino acids 10–23) and unlabeled peptides for binding to purified I-Ag7,
measured by ELISA (see Materials and Methods). Unlabeled HEL 10–23
(u) was used as an internal control in each 96-well plate assay; j, good
binder (IC50 100 nM); m, weak binder (IC50 2000 nM); n, non-binder
(IC50 50,000 nM). 
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were coincubated with 
 
z
 
200 ng of I-A
 
g7
 
 protein in U-bottomed
polypropylene 96-well plates (Costar Serocluster, Costar Corp.,
Cambridge, MA) in binding buffer at RT. The binding buffer
was 6.7 mM citric phosphate, pH 7.0, with 0.15 M NaCl, 2%
NP-40, 2 mM EDTA, and the protease inhibitors as used in the
lysis buffer. After a minimum of 24 h, each incubate was trans-
ferred to the corresponding well of an ELISA plate (Nunc Max-
isorp, Nunc, Roskilde, Denmark) containing prebound OX-6
antibody (5 
 
m
 
g/ml overnight at 4
 
8
 
C, followed by washing). After
incubation at RT for at least 2 h, and washing, bound biotiny-
lated peptide–I-A
 
g7
 
 complexes were detected colorimetrically at
405 nm after reaction with streptavidin–alkaline phosphatase and
paranitrophenolphosphate. Competition binding curves were plotted
and the affinity of peptide for I-A
 
g7
 
 was expressed as an inhibitory
concentration 50 (IC
 
50
 
), the concentration of peptide required to
inhibit the binding of bio-HEL 10–23 by 50%.
 
Results and Discussion
 
I-A
 
g7
 
 Purification and Binding Assay.
 
Approximately 2 mg
of protein, estimated by Coomassie blue binding (Bio Rad
Protein assay), was purified from 5 
 
3
 
 10
 
10
 
 4G4.7 cells. In
SDS-PAGE, the majority (.95%) of the protein was re-
solved as two bands of molecular weight z33,000 and
z28,000 that correspond to the a and b subunits, respec-
Table 1. Truncation Analysis of I-Ag7–restricted HEL 9–27 Epitope
H E L 91 01 11 21 31 41 51 61 71 81 92 02 12 22 32 42 52 62 7
Binding to
I-Ag7 IC50 
Activation of
T cell hybridoma
SC50 
nM
9–27 A A A M K R H G L D N Y R G Y S L G N 350 60
10–27 A A M K R H G L D N Y R G Y S L G N 300 84
11–27 A M K R H G L D N Y R G Y S L G N 300 84
12–27 M K R H G L D N Y R G Y S L G N 300 380
13–27 K R H G L D N Y R G Y S L G N 300 3,000
14–27 R H G L D N Y R G Y S L G N 2,000 .10,000
15–27 H G L D N Y R G Y S L G N 20,000 .10,000
16–27 G L D N Y R G Y S L G N .50,000 .10,000
17–27 L D N Y R G Y S L G N .50,000 .10,000
18–27 D N Y R G Y S L G N .50,000 .10,000
19–27 N Y R G Y S L G N .50,000 .10,000
9–26 A A A M K R H G L D N Y R G Y S L G 300 60
9–25 A A A M K R H G L D N Y R G Y S L 300 140
9–24 A A A M K R H G L D N Y R G Y S 200 72
9–23 A A A M K R H G L D N Y R G Y 150 180
9–22 A A A M K R H G L D N Y R G 300 240
9–21 A A A M K R H G L D N Y R 300 360
9–20 A A A M K R H G L D N Y 150 .10,000
9–19 A A A M K R H G L D N 15,000 .10,000
9–18 A A A M K R H G L D .15,000 .10,000
9–17 A A A M K R H G L .50,000 .10,000
12–23 M K R H G L D N Y R G Y 250 800
12–22 M K R H G L D N Y R G 600 Not done
12–21 M K R H G L D N Y R 1,000 1,200
12–20 M K R H G L D N Y 1,250 .10,000
13–23 K R H G L D N Y R G Y 200 Not done
13–22 K R H G L D N Y R G 250 Not done
13–21 K R H G L D N Y R 5,000 .10,000
13–20 K R H G L D N Y 30,000 .10,000
14–23 R H G L D N Y R G Y 500 Not done
14–22 R H G L D N Y R G 3,000 Not done1016 Peptide-binding Motif for I-Ag7
tively, of mouse class II MHC molecules (data not shown).
The competition binding assay with purified I-Ag7 was sen-
sitive and specific (Fig. 1), and highly reproducible; in 15
separate assays the mean 6 SD of the IC50 for competition
between biotinylated and unlabeled HEL 10–23 was 295 6
72 nM.
Carrasco-Marin et al. (8) were unable to demonstrate di-
rect binding of HEL 11–25 to purified I-Ag7 and proposed
that I-Ag7 was inherently unstable. We found that purified
I-Ag7 stored at 2708C for more than 1 yr reproducibly
bound HEL 10–23 with high affinity. Therefore, our re-
sults do not support their hypothesis that I-Ag7 is inherently
unstable, which they postulated would impair its ability to
bind and induce tolerance to autoreactive peptides.
Truncation Analysis of HEL 9–27. Peptides representing
sequential truncations of HEL 9–27, from either the NH2
or COOH-terminus, were each assayed in parallel for
binding to I-Ag7 and for their ability to activate the 2D12.1
hybridoma. Inspection of these data (Table 1) reveals that
the minimum T cell epitope is M12-R21, and the mini-
mum binder is M12-Y20 or K13-R21.
Effect of Selected Substitutions on Binding and Bioactivity of
HEL 12–22. Substitution of alanine (A) at each position
in HEL 12–22 (Table 2) had no significant effect on bind-
ing, with the sole exceptions of positions L17 and Y20.
Substitution at either of these two positions virtually abol-
ished binding. On the other hand, while having no effect
on binding, substitutions by A at K13, R14, H15, G16,
and D18, and to a lesser extent at R21, abolished T cell ac-
tivation. Removal of R21 (see Table 1) abolished T cell
activation. Further substitutions of representative amino ac-
ids (D, K, P, Y, L, Q) at each position (Table 2) revealed
varying levels of tolerance of specific residues/positions for
binding (see below) and generally confirmed the results of
the alanine substitutions on T cell activation. On the basis
of these results, we can deduce that most residues in the
minimal T cell epitope HEL 12–21 have TCR contacts
and that two, L17 and Y20, are essential for binding to I-Ag7
(Fig. 2).
Anchor Residues for Peptide Binding. The critical roles of
L17 and Y20 in the HEL epitope, as model anchor residues
for binding to I-Ag7, was demonstrated with poly(A) pep-
Table 2. Effect of Selected Amino Acid Substitutions on Binding and T Cell Activation of HEL 10–22*
Substi-
tuted
amino
acid
HEL 10–22
10
A
11
A
12
M
13
K
14
R
15
H
16
G
17
L
18
D
19
N
20
Y
21
R
22
G
ALA (A) 22 600‡ 300 300 300 400 30,000 150 150 30,000 800 350
22 46§ 8,000 .10,000 .10,000 .10,000 .10,000 .10,000 42 10,000 2,200 45
ASP (D) 950 950 950 950 7,500 1,750 2,000 7,500 2 2,000 7,000 750 150
48 48 60 1,200 800 600 2,000 1,600 2 1,100 1,100 1,300 200
LYS (K) 160 750 500 2 900 800 1,500 7,000 600 7,000 900 350 1,500
200 100 60 2 200 .10,000 4,750 3,000 3,000 3,500 4,750 200 250
PRO (P) 1,300 1,300 1,300 1,300 2,500 7,000 2,500 10,000 300 450 10,000 350 650
240 240 400 9,000 9,000 .10,000 .10,000 .10,000 .10,000 .10,000 8,000 1,000 5,000
TYR (Y) 275 350 125 250 900 150 750 3,500 100 .50,000 2 300 300
270 155 310 .10,000 .10,000 .10,000 4,000 4,900 .10,000 .10,000 2. 10,000 .10,000
LEU (L) 300 400 550 1,100 750 450 1,400 2 75 1,450 1,550 500 1,500
270 400 .10,000 .10,000 10,000 .10,000 .10,000 2. 10,000 .10,000 .10,000 5,370 350
GLN (Q) 450 450 600 900 550 400 700 12,000 200 2,000 2,000 700 900
25 47 38 2,250 .10,000 .10,000 475 .10,000 .10,000 .10,000 .10,000 650 142
*For natural, unsubstituted HEL 10–22, the binding affinity for I-Ag7 (IC50; mean 6 SD) was 295 6 72 nM (n 5 15) and the dose (SC50) for activa-
tion of the T cell hybridoma was 52 6 23 nM (n 5 6).
‡Binding to I-Ag7: IC50 (nM).
§Activation of the T cell hybridoma 2D12.1: SC50 (nM).
Figure 2. Minimal T cell epitope, HEL 12(M)–21(R), showing TCR
contact residues and L and Y primary anchors for binding to I-A97 at rela-
tive positions 6 and 9, and positions 3 and 8 at which specific residues are
also not tolerated for binding.1017 Harrison et al.
tides (Table 3). The nonbinding poly(A) peptide, KAA
AAAAAA, was converted to a super binder simply by in-
corporating L and Y at the same relative positions as in the
HEL epitope. Either residue alone was not sufficient. Bind-
ing was reconstituted only when these two residues were
appropriately spaced and in the correct order. In addition,
this approach reveals the importance of the frame or con-
text of the anchor residues. The LAAY sequence must be
flanked by at least two As, an absence of which at the
COOH terminus can be compensated for by at least three
As on the NH2 terminus, but not vice versa. This suggests
that binding of these specific residues within the I-Ag7
groove requires stabilization by hydrogen bonding from
nonspecific flanking residues, in particular at the NH2 ter-
minus. For the purpose of further analysis, the relative posi-
tions (p) of L and Y in the HEL epitope 12–21 are desig-
nated p6 and p9.
Effect of Multiple Substitutions at p6 and p9. In addition to
the selected substitutions at all positions (see Table 2), we
investigated the effect on binding of all possible substitu-
tions (except labile cysteine) at p6 or p9. A single residue
substitution was classified as well tolerated, weakly toler-
ated, or nontolerated according to a threshold on its IC50
value: well tolerated, ,1,000 nM; weakly tolerated, 1,000–
10,000 nM; nontolerated, >10,000 nM. Although some-
what arbitrary, this classification corresponds to generally
accepted notions of good binders, moderate binders, and
weak to non-binders. The results, combined with those
from Table 2, are presented in Table 4. Optimally, p6 is a
large, hydrophobic residue (L, I, M, V), whereas p9 is aro-
matic and hydrophobic (Y, F) or positively charged (K, R).
Most amino acids are not well tolerated at these anchor po-
sitions. Additionally, specific amino acids are not tolerated
at other positions, namely F and E at p3 and W and Y at
p8. This information allowed us to propose and test minimum
rules for a motif for I-Ag7 binding peptides. These were that
a binder must have the following: (a) two well-tolerated res-
idues or one well-tolerated and one weakly-tolerated residue
at anchor positions p6 and p9, (b) no nontolerated residues
at positions p3 and p8, and (c) at least two residues flanking
p6 and p9, or at least three residues NH2-terminal of p6.
Motifs in Peptides Known or Deduced to Bind I-Ag7. Rela-
tively few peptides containing sequences that might bind to
I-Ag7 have been reported in the literature. They include
peptides that stimulate I-Ag7–restricted T cells or T cell
hybridomas, compete for antigen presentation to T cell hy-
bridomas, induce EAE in Biozzi AB/H mice, or have been
eluted from I-Ag7 (listed in Table 5). It should be noted
Table 3. Binding to I-Ag7 of L- and Y-substituted Poly(A) Peptides
Peptide
Binding IC50
(nM)
*KAAAAAAAA 25,000
KAAALAAAA 25,000
KAAAAAAYA 20,000
KAAALAAYA 5 0
AAAALAAYA 5 0
A A A A Y A A L A 12,000
A A A L A A A Y A 12,000
A A A A A L A Y A 12,000
AAAAALAAY 2 5
AAAALAAY 2 0 0
AAALAAYA 6 0 0
AAALAAYAA 1 5 0
AALAAYAA 4 0 0
A A L A A Y A 20,000
ALAAYAAAA 6,000
A L A A Y A 30,000
LAAYAAAAA 35,000
*K added at NH2 terminus to improve solubility.
Table 4. Effects of Amino Acid Substitutions on Binding of
HEL 12–22 to I-Ag7
Relative position (HEL 12–22)
1
M
2
K
3
R
4
H
5
G
6
L
7
D
8
N
9
Y
10
R
11
G
Well-tolerated residues A A A A A I A A F A A
(IC50 ,1,000 nM) D D K K Q M E G K D D
KQLLYVKPRK P
LYQQ LS LQ
QY Y P P Y
YQ Q
RY
Y
Weakly tolerated residues P L D D D D D D K
(IC50 1,000–10,000 nM) P G P K F E H L
PL H F L
WP KK M
SN L N
TQ Q
YR W
Nontolerated E A W A
(IC50 .10,000 nM) F E Y E
GG
PI
QP
RS
ST
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that apart from the present study and that of Carrasco-
Marin et al. (8), binding has not been determined by direct
peptide interaction with purified I-Ag7, but either by elution
from I-Ag7, competition with peptides that activate I-Ag7–
bearing T cell hybridomas or induction of EAE. The motif
we have defined correctly identifies 27/30 (90%) of the
published sequences (Table 5). Interestingly, we found that
one of these sequences, mouse serum albumin 560–574, that
does not contain the motif, did not bind to I-Ag7 (data not
shown).
Two groups have suggested putative motifs for peptides
that bind to I-Ag7. Reich et al. (7) found that several pep-
tides eluted from I-Ag7 had an acidic residue at the COOH
terminus. Their data also indicated that this residue was
separated by three from a basic residue. Whereas basic resi-
dues are major p9 anchors in our motif, an acidic residue at
the COOH terminus is not a uniform feature of other pep-
tides deduced (Table 5) or shown (Table 6) to bind to I-Ag7.
However, it is conceivable that in some cases, e.g., OVA
323–339 (see Table 5), a COOH-terminal acidic residue
could compensate for a nontolerated residue at p9. Amor et al.
(9) described a possible motif shared by encephalitogenic
peptides in the Biozzi AB/H (I-Ag7) mouse. It contained
hydrophobic (I or L), basic (K, R, or H), a small T cell
contact (A or G) and large hydrophobic (L or F) residues
within a 6– to 7–amino acid core. They studied the effect
of K substitutions on the immunogenicity of phospholipid
protein 56–70 (see Table 5), in which they had deduced a
core sequence, NVIHAFQ, necessary for the induction of
EAE. This sequence contains our motif I (p6) and F (p9).
K substitutions at I, H, A, or F completely abolished the
ability of the peptide to induce EAE. We would have pre-
dicted abolition of binding by the K substitution at I or A
and, by analogy with HEL (see Table 2), a significant re-
duction in T cell activation by K substitution at H or F.
Thus, the features of this encephalitogenic motif are con-
tained within the expanded and generalized motif we have
described.
Presence of Motif in Overlapping Peptides from Human Proin-
sulin. We tested peptides overlapping by four residues and
spanning the entire sequence of human proinsulin for bind-
ing to I-Ag7, and inspected them for presence of the bind-
ing motif (Table 6). All six (100%) good binders contained
a motif. However, a motif was present in 4/13 (30%) weak
or non-binders. Clearly, the motif rules do not fully ac-
count for the effects of residue combinations or flanking se-
quences. Proinsulin 5–19 has a well-tolerated V at p6 and a
weakly tolerated L at p9 yet did not bind, but when this
anchor pair moves towards the NH2 terminus in the fol-
lowing 9–23 sequence, the peptide becomes a binder. Pro-
insulin 45–59 has a well-tolerated L at p6 and a weakly tol-
erated L at p9 and binds with high affinity, but when this
anchor pair moves towards the NH2 terminus in the fol-
lowing 49–63 sequence, the affinity of the peptide de-
creases. Human proinsulin 17–31 has a weakly tolerated Y
at p6 and a well-tolerated K at p9, yet does not bind. Al-
though this anchor pair is close to the COOH terminus,
this does not preclude other peptides, e.g., human proinsu-
lin 65–79, from binding with high affinity. However, hu-
man proinsulin 17–31 has a positively charged p9/COOH
terminus, whereas the other binding peptides are generally
neutral or tend to be acidic. Reich et al. (7) noted a bias to-
wards acidic residues at the COOH termini of peptides
they eluted from I-Ag7. When the anchor pair in this pep-
tide moves towards the NH2 terminus in the following 21–
35 sequence with an acidic COOH terminus, the peptide
becomes a binder. Thus, in a small set of unbiased peptides,
the motif appears to have high sensitivity and some degree
of specificity. A similar degree of specificity was found for
an I-Ek motif by correlating binding with the presence of
the motif in a panel of z150 peptides (23).
Although the core region length of class II MHC bind-
ing peptides is z13 residues (24), analysis of binding motifs
(25) indicates that only nine residues within the core region
are essential for binding. The motif we describe conforms
with this requirement. It is simplistic in the sense that each
residue is assumed to contribute to binding independently
of other residues and, when located at a given position, to
contribute the same amount to binding even within differ-
ent sequences. The rules that govern binding to class II
MHC molecules are more complex and will have to take
account of interactions between residues. Nevertheless, by
defining tolerated and nontolerated residues for binding at
Table 6. Overlapping Human Proinsulin Peptides Tested for 
Binding to I-Ag7
Peptide sequence
IC50
(nM) Motif
(1–15) F V NQHLAGSHLVEAL 7,000 2
(5–19) H L A GSHLVEALYLVA 30,000 1
(9–23) S H L V EALYLVAG E R G 1,000 1
(13–27) E A LYLVAG E R G F F Y T 4,000 2
(17–31) L V A G E R G F F Y TPKTR. 50,000 1
(21–35) E R G F F Y TPKTRRE A E 1,000 1
(25–39) F Y TPKTRRE A E D L Q V 1,000 1
(29–43) K TRRE A E D L Q V G Q V E 7,000 2
(33–47) E A E D L Q V G Q V E L G G G .50,000 2
(37–51) L Q V G Q V E L G G G P G A G .50,000 2
(41–55) Q V E L G G G P G A G S L Q P 6,000 2
(45–59) G G G P G A G S L QPLA L E 200 1
(49–63) G A G S L QPLA L E G S L Q 1,000 1
(53–67) L QPLALeGSLQKRG I 25,000 2
(57–71) A L e GSLQKRGIVEQ A 15,000 2
(61–75) S L QKRGIVEQ AAT S I 12,000 2
(65–79) R G I V E Q AATSIASLY 400 1
(69–83) E Q AATSIASLYQLE N 12,000 1
(73–86) T S I A S L YQLENYAN 10,000 1
Residues well tolerated at the p6 or p9 anchor positions (see Table 4)
are bolded; weakly tolerated are underlined; nontolerated are bolded in
lower case. Cysteines have been substituted by alanine (A in italics).1020 Peptide-binding Motif for I-Ag7
key positions in HEL 12–22, we appear to have unearthed
general rules that identify a large majority of known bind-
ers to I-Ag7, and discriminate most non-binders.
The high sensitivity of the motif for reported I-Ag7 bind-
ers or T cell epitopes is remarkable, but the utility of the
motif will depend on its specificity, i.e., its absence in non-
binders. Specificity was 70% for the peptides in Table 6,
but the database is small. Even if somewhat degenerate in
its present form, the motif should considerably narrow the
search for possible binders. The I-Ag7 binding assay we
have described is robust and will enable the database of
binders and non-binders to be enlarged progressively to
further validate the motif. Experiments to fine tune the
motif by using peptide libraries are in progress. Just as a
motif for human class II DR4 (*0401) binding peptides was
applied to scan candidate autoantigen proteins in rheuma-
toid arthritis for potential epitopes (26), so also might the
motif for I-Ag7 binding be applied to identify potential au-
toepitopes for IDDM in NOD mice and CR-EAE in
Biozzi AB/H mice.
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